LDN for Rare Cancers: Case Study in Lynch Syndrome

This presentation explores the role of Low Dose Naltrexone (LDN) in managing rare cancers, specifically focusing on Lynch Syndrome. A compelling case study of a 65-year-old female patient with a history of multiple cancers is detailed, highlighting her remarkable recovery after restarting LDN treatment.

Dr. Deanna Windham, DO:  So, this is one case study of one of my patients who is currently 65 years old. She's had multiple forms of cancer beginning in her late 20s. They were all treated traditionally. She had colon cancer first, ovarian cancer second, and she came to me in 2009 after the she had already been treated uh for the ovarian cancer. We started her on lodtos nalrexone and explored and treated her triggers. Um she stayed cancerree but was lost to followup in 2018. In 2022, um, she followed up with me again and she'd gone off her entire plan, including her lowto nrexone, and she'd been diagnosed with brain cancer. We restarted her on LDN again. We went through the triggers, explored and treated those. She went through treatment unexpectedly well. She actually worked in her hospital bed and said that if she wasn't in a hospital, she would not even know she had cancer and she just she had no decrease in energy. She felt great. We she was on lowdose nrexone in the hospital. Her oncologist knew about it and was supportive. And we also had her on nutrients and supplements treating um her genetic and epigenetic risk factors. And now in 2024, she currently has no evidence of disease. She is completely free of cancer and she is still committed to a path that includes annual circulating tumor cell testing to improve her health and longevity.